These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25679319)

  • 1. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
    Sudhakar N; Priya Doss CG; Thirumal Kumar D; Chakraborty C; Anand K; Suresh M
    J Biomol Struct Dyn; 2016; 34(1):29-41. PubMed ID: 25679319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
    Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
    Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
    Kumar DT; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in head and neck squamous cell carcinoma.
    Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
    Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
    Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
    J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].
    Liu P; Li DJ; Qin HD; Zhang RH; Chen LZ; Zeng YX
    Ai Zheng; 2007 Jan; 26(1):15-20. PubMed ID: 17222361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
    Shah S; Shah S; Padh H; Kalia K
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):628-35. PubMed ID: 26453385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
    Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
    Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
    Mangone FR; Bobrovnitchaia IG; Salaorni S; Manuli E; Nagai MA
    Clinics (Sao Paulo); 2012 Nov; 67(11):1285-90. PubMed ID: 23184205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.